JACC Basic to Translational Science · 2021 · 47 citations · 25 references
Life SciencesCardiologyImmunologyImmunopharmacologyInflammationInnate ImmunityAnti-inflammatory PharmacologyCytokine BiologyCytokine Receptor SignalingCytokine RegulationCytokine-based TherapyInflammatory SignalingCardiac Systolic FunctionCytokine AntagonismInfarct ExpansionInflammation In Cardiovascular DiseaseInterleukin-6 InhibitionInterleukin-6 InhibitorsRecombinant Fusion ProteinsTherapeutic Target Identification
Interleukin (IL)-6 is an emerging therapeutic target in myocardial infarction (MI). IL-6 has 2 distinct signaling pathways: trans-signaling, which mediates inflammation, and classic signaling, which also has anti-inflammatory effects. The novel recombinant fusion protein sgp130Fc achieves exclusive trans-signaling blockade, whereas anti-IL-6 antibodies (Abs) result in panantagonism. In a rat model of reperfused MI, sgp130Fc, but not anti-IL-6-Ab, attenuated neutrophil and macrophage infiltration into the myocardium, reduced infarct size, and preserved cardiac function 28 days after MI. These data demonstrate the efficacy of exclusive IL-6 trans-signaling blockade and support further investigation of sgp130Fc as a potential novel therapy in MI.
25
Role of IL-6 and Its Soluble Receptor in Induction of Chemokines and Leukocyte Recruitment
Maria Romano, Marina Sironi, Carlo Toniatti et al. · Immunity · 1997 · 1.1K citations · Full text
IL-6 Regulates Neutrophil Trafficking during Acute Inflammation via STAT3
Ceri A. Fielding, Rachel M. McLoughlin, Louise McLeod et al. · The Journal of Immunology · 2008 · 408 citations · Full text